Tagged Articles

non-Hodgkin lymphoma 5 articles

First Roundup trial in federal court to begin February 2019

U.S. District Judge Vince Chaabria selected the first federal trial accusing Monsanto’s glyphosate-containing weed killers of causing cancer. The case of California resident Edwin Hardeman will be tried as a bellwether among more than 620 pending in the federal litigation in February 2019. The trial is scheduled six months after the first case among more than 9,000 went to trial in a California state court. School groundskeeper DeWayne “Lee” Jackson was awarded $289 million after a jury found that his regular use of Monsanto’s Roundup and Ranger Pro herbicides caused him to develop non-Hodgkin lymphoma. His award was later reduced ... Read More

Incidences of Blood Cancer are Significantly Higher Near Plants that Release Benzene

Non-Hodgkin lymphoma is a blood cancer that has been on the rise in the last few decades, likely due to the increase of industrial production throughout the U.S. Many refineries and plants release a chemical carcinogen called benzene that is linked to blood cancers such as non-Hodgkin lymphoma. Catherine Bulka, MPH, used data from the Environmental Protection Agency (EPA) U.S. Census Bureau to check patterns of non-Hodgkin lymphoma cases that occurred between 1999 and 2008 throughout the state of Georgia. She worked with Dr. Christopher Flowers his team in the Lymphoma Program at Emory University to analyze new cases of the blood cancer and the ... Read More

Study finds chemical exposure may have increased cancer rates in IBM employees

Employees at IBM’s Endicott, New York, facility may have been prone to develop certain types of cancer and other disease due to exposure to tetrachloroethylene (PCE) and other toxic chemicals in the workplace, according to the results of a government-led statistical analysis. Endicott residents concerned about toxic exposure at IBM pushed for the study, which researchers with the National Institute for Occupational Safety and Health (NIOSH) conducted during a five-year period using $3.1 million in federal funding. The comprehensive analysis examined the health of 34,494 workers who were employed at IBM’s Endicott facility between 1969 and 2001. The study found ... Read More

Old drug found to be key treatment for non-Hodgkin lymphomas

A drug developed 50 years ago has reemerged as a new weapon in the fight against certain types of non-Hodgkin lymphomas, more than doubling progression-free survival rates and reducing side effects compared to a multi-drug cocktail that for years has been used to treat indolent non-Hodgkin lymphomas. The drug, bendamustine (Treanda), showed promising results when combined with another therapy, rituximab (Rituxan). Traditionally, the disease has been treated with a combination of five different drugs – rituximab, cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine, and prednisone – called R-CHOP. Findings on bendamustine were presented this week at the annual meeting of the American ... Read More

Women with breast implants may be at risk for rare type of cancer

Women with saline or silicone gel-filled breast implants may be at risk for developing anaplastic large cell lymphoma (ALCL), a very rare type of cancer, the Food and Drug Administration (FDA) announced. The agency reviewed data in which there were 60 cases of ALCL in women with breast implants worldwide. An estimated 5 million to 10 million women worldwide have breast implants. ALCL is a type of non-Hodgkin lymphoma that appears in different parts of the body including the lymph nodes and skin. In women with breast implants, ALCL has been found in the scar capsule adjacent to the implant. Each ... Read More